Literature DB >> 29264937

Rationale and design of the IMPACT EU-trial: improve management of heart failure with procalcitonin biomarkers in cardiology (BIC)-18.

Martin Möckel1, Anna Slagman1, Jörn Ole Vollert2, Stefan Ebmeyer2, Jan C Wiemer2, Julia Searle1, Evangelos Giannitsis3, John A Kellum4, Alan Maisel5.   

Abstract

OBJECTIVES: To evaluate the effectiveness of procalcitonin (PCT)-guided antibiotic treatment compared to current treatment practice to reduce 90-day all-cause mortality in emergency patients with shortness of breath (SOB) and suspected acute heart failure (AHF).
BACKGROUND: Concomitant AHF and lower respiratory tract (or other bacterial) infection in emergency patients with dyspnea are common and can be difficult to diagnose. Early and adequate initiation of antibiotic therapy (ABX) significantly improves patient outcome, but superfluous prescription of ABX maybe harmful.
METHODS: In a multicentre, prospective, randomized, controlled process trial with an open intervention, adult emergency patients with SOB and increased levels of natriuretic peptides will be randomized to either a standard care group or a PCT-guided group with respect to the initiation of antibiotic treatment. In the PCT-guided group, the initiation of antibiotic therapy is based on the results of acute PCT measurements at admission, using a cut-off of 0.2 ng/ml. A two-stage sample-size adaptive design is used; an interim analysis was done after completion of 50% of patients and the final sample size remained unchanged. Primary endpoint is 90-day all-cause mortality.
CONCLUSIONS: The current study will provide evidence, whether the routine use of PCT in patients with suspected AHF improves outcome.

Entities:  

Keywords:  Acute heart failure; antibiotic therapy; procalcitonin

Mesh:

Substances:

Year:  2018        PMID: 29264937     DOI: 10.1080/1354750X.2017.1420823

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  2 in total

Review 1.  Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).

Authors:  Wouter C Meijers; Antoni Bayes-Genis; Alexandre Mebazaa; Johann Bauersachs; John G F Cleland; Andrew J S Coats; James L Januzzi; Alan S Maisel; Kenneth McDonald; Thomas Mueller; A Mark Richards; Petar Seferovic; Christian Mueller; Rudolf A de Boer
Journal:  Eur J Heart Fail       Date:  2021-10-10       Impact factor: 17.349

2.  Early identification of acute heart failure at the time of presentation: do natriuretic peptides make the difference?

Authors:  Martin Möckel; Stephan von Haehling; Jörn O Vollert; Jan C Wiemer; Stefan D Anker; Alan Maisel
Journal:  ESC Heart Fail       Date:  2018-04-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.